Table 1 Clinical and pathological characteristics of patients with and without Her-2/neu overexpression, c-Kit expression and EGFR expression

From: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Characteristics

All patients ( n =54)

EGFR− ( n =18)

EGFR+ ( n =36)

HER2/neu− ( n =52)

HER2/neu+ ( n =2)

c-KIT− ( n =48)

c-KIT+ ( n =6)

Age (years)

 Median

58

58

55.5

58

52

55.5

66.5

 Range

33–73

33–68

41–73

33–73

45–59

33–73

48–71

Sex

 Male

31 (57%)

10 (55%)

21 (58%)

29 (56%)

2 (100%)

29 (60%)

2 (33%)

 Female

23 (43%)

8 (45%)

15 (42%)

23 (44%)

0

19 (40%)

4 (67%)

Pathology

 Adenocarcinoma

29 (53%)

10 (55%)

19 (53%)

27 (52%)

2 (100%)

27 (56%)

2 (33%)

 Poorlydifferentiated

18 (33%)

7 (38%)

11 (30%)

18 (35%)

0

16 (33%)

2 (33%)

 Undifferentiated

7 (13%)

1 (5%)

6 (17%)

7 (13%)

0

5 (11%)

2 (33%)

Treatment

 1

28 (51%)

7 (38%)

21 (58%)

27 (52%)

1 (50%)

27 (56%)

1 (17%)

 2

26 (49%)

11 (62%)

15 (42%)

25 (48%)

1 (50%)

21 (44%)

5 (83%)

Serum LDH

 Normal

26 (48%)

9 (50%)

17 (47%)

26 (50%)

0

23 (48%)

3 (50%)

 Elevated

22 (40%)

8 (45%)

14 (39%)

21 (40%)

1

19 (40%)

3 (50%)

 Not available

6 (12%)

1 (5%)

5 (14%)

5

1

6

0

ECOG PS

 0

43 (79.5%)

14 (78%)

29 (80%)

41 (79%)

2

38 (79%)

5 (83%)

 1

10 (18.5%)

4 (22%)

6 (17%)

10 (19%)

0

9 (19%)

1 (17%)

 Not available

1

 

1

1

0

1

0

Tumour site

 Lymph nodes

32 (60%)

10 (55%)

25 (70%)

35 (67%)

2 (100%)

36 (75%)

4 (66%)

 Liver

27 (50%)

11 (60%)

16 (44%)

27 (52%)

0

25 (52%)

2 (33%)

 Lung

28 (52%)

11 (60%)

17 (47%°

26 (50%)

2 (100%)

26 (54%)

2 (33%)

 Bone

19 (35%)

9 (50%)

10 (28%)

18 (35%)

1 (50%)

18 (37%)

0

 Peritoneum

3 (5%)

3 (16%)

9 (25%)

3 (6%)

0

3 (6%)

0

 Adrenal gland

6 (11%)

1 (5%)

5 (14%)

12 (23%)

0

6 (12%)

0

 Pleura

4 (7%)

1 (5%)

3 (8%)

4 (8%)

0

4 (8%)

0

 Brain

2 (4%)

0

2 (5%)

2 (4%)

0

1 (2%)

1 (17%)

 Cutaneous

1 (2%)

0

1 (2.5%)

1 (2%)

0

1 (2%)

0

 Others

10 (18%)

4 (22%)

6 (17%)

10 (19%)

0

10 (21%)

0

  1. EGFR-negative tumour patient: EGFR score 1+.
  2. EGFR-positive tumour patient: EGFR score 2+ or 3+.
  3. Treatment 1: cisplatin and gemcitabin.
  4. Treatment 2: cisplatin and irinotecan.